MLchartDataset catalogue

prostatic acid phosphatase-sargramostim fusion protein PA2024

Term · Oncology and biomedicine · MLC-T-ONC-016254

A genetically-engineered protein formed by the fusion of prostatic acid phosphatase (PAP) and sargramostim (GM-CSF). Vaccination with antigen-presenting cells (APC) loaded with prostatic acid phosphatase-sargramostim fusion protein may elicit a cytotoxic T-cell response against tumor cells that express PAP.

Table 1. Record
IdentifierMLC-T-ONC-016254
FieldOncology and biomedicine
SynonymsPA2024; prostatic acid phosphatase-sargramostim fusion protein
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-016254",
  "term": "prostatic acid phosphatase-sargramostim fusion protein PA2024",
  "field": "Oncology and biomedicine",
  "definition": "A genetically-engineered protein formed by the fusion of prostatic acid phosphatase (PAP) and sargramostim (GM-CSF). Vaccination with antigen-presenting cells (APC) loaded with prostatic acid phosphatase-sargramostim fusion protein may elicit a cytotoxic T-cell response against tumor cells that express PAP.",
  "synonyms": [
    "PA2024",
    "prostatic acid phosphatase-sargramostim fusion protein"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/prostatic-acid-phosphatase-sargramostim-fusion-protein-pa2024/"
}

Record 13,734 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.